Plus Therapeutics (PSTV) Cash from Financing Activities (2010 - 2026)
Plus Therapeutics (PSTV) reported Cash from Financing Activities of $9.0 million for Q1 2026, down 27.17% year-over-year from $12.4 million in Q1 2025, and up 222.33% quarter-over-quarter from $2.8 million in Q4 2025.
Plus Therapeutics (PSTV) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has 17 years of Cash from Financing Activities data on file, last reported at $9.0 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $9.0 million, down 27.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.9 million (up 39.1% YoY), and the FY2025 annual result was $30.3 million, up 389.91% from the prior year.
- Cash from Financing Activities rose to $9.0 million in Q1 2026 per PSTV's latest filing, from $2.8 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $12.4 million in Q1 2025 and troughed at -$776000.0 in Q1 2024.
- A 5-year average of $4.2 million and a median of $2.8 million in 2025 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities tumbled 634.34% in 2023, then surged 1698.58% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $99000.0 in 2022, then plunged by 634.34% to -$529000.0 in 2023, then surged by 1416.26% to $7.0 million in 2024, then slumped by 59.74% to $2.8 million in 2025, then soared by 222.33% to $9.0 million in 2026.
- Business Quant data shows PSTV's Cash from Financing Activities at $9.0 million in Q1 2026, $2.8 million in Q4 2025, and $12.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 85,464.43 |
| 10 | Plus Therapeutics | 34.26 Mn | 19.15 Mn | - | 9.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.04 Mn |
| Mar 31, 2026 | 9.04 Mn |
| Dec 31, 2025 | 2.80 Mn |
| Dec 31, 2025 | 2.80 Mn |
| Sep 30, 2025 | 12.31 Mn |
| Sep 30, 2025 | 12.31 Mn |
| Jun 30, 2025 | 2.80 Mn |
| Jun 30, 2025 | 2.80 Mn |
| Mar 31, 2025 | 12.41 Mn |
| Mar 31, 2025 | 12.41 Mn |
| Jun 30, 2024 | 6.96 Mn |
| Jun 30, 2024 | 6.96 Mn |
| Mar 31, 2024 | -776,000.00 |
| Mar 31, 2024 | -776,000.00 |
| Dec 31, 2023 | -529,000.00 |
| Dec 31, 2023 | -529,000.00 |
| Sep 30, 2023 | 2.52 Mn |
| Sep 30, 2023 | 2.52 Mn |
| Jun 30, 2023 | 961,000.00 |
| Jun 30, 2023 | 961,000.00 |